RxDoctor Payments Data

Glenn Tovar Dias, MD

Internal Medicine · Fort Myers, FLNPI 1598867251

Payments from drug & device makers

$9,782in general payments, 2019–2025

Across 543 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Novo Nordisk$991
  • AstraZeneca$951
  • Novartis$651
  • Amarin Pharma, Inc.$640
  • Lilly USA, LLC$574
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,67099%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,782 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$695,227
Medicare patients
884
Services billed
14,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide149$208,770
EliquisApixaban162$203,566
Repatha SureclickEvolocumab96$128,995
JardianceEmpagliflozin72$113,571
XareltoRivaroxaban63$84,534
TrulicityDulaglutide57$82,582
FarxigaDapagliflozin Propanediol63$79,210
MounjaroTirzepatide37$49,088
JanuviaSitagliptin Phosphate34$45,294
RybelsusSemaglutide13$29,916
GlyxambiEmpagliflozin/Linagliptin22$26,542
VascepaIcosapent Ethyl20$18,792
JanumetSitagliptin Phos/Metformin Hcl19$14,820
Praluent PenAlirocumab16$12,010
Rosuvastatin Calcium966$11,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$991$238,685162 claims
PfizerEliquis$237$203,566162 claims
Boehringer IngelheimJardiance, Glyxambi$459$140,11294 claims
Lilly USA, LLCTrulicity, Mounjaro$574$131,67094 claims
AstraZenecaFarxiga, Brilinta, Symbicort$951$96,09697 claims
Johnson & JohnsonXarelto$573$84,53463 claims
MerckJanuvia, Janumet$469$60,11453 claims
Esperion Therapeutics, Inc.Nexletol$224$8,40715 claims
AbbVieSynthroid$271$7,035111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →